Absence of "cheese effect" during deprenyl therapy: some recent studies.
Although the selective monoamine oxidase (MAO) B inhibitor, (-)deprenyl, has been shown to be free from the "cheese effect" in man after tyramine challenge, the reason for this is far from clear: it may well be independent of the selective inhibitory action of the drug, for during chronic administration there is some evidence to suggest that both A and B forms of the enzyme are equally inhibited. By-passing the putative MAO A gut barrier in the pig (chosen because it possesses MAO B alone in all other tissues) by intravenous tyramine administration into the deprenyl-pretreated animal failed to provoke a pressor response, despite substantial MAO inhibition. Conversely, clorgyline (MAO A inhibitor) pretreatment, which resulted in minimal MAO inhibition, produced a profound hypertensive response, resembling that observed with the non-MAO-inhibiting drug, isoniazid. The most parsimonious explanation for these findings may be that two separate but closely associated pharmacological effects are normally found with "orthodox" MAO inhibitors, enzyme inhibition proper and facilitation of noradrenaline release from its binding sites during tyramine challenge.
D000662:Amphetamines / Q000378:metabolism; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D007422:Intestines / Q000201:enzymology; D008995:Monoamine Oxidase / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013379:Substrate Specificity; D013552:Swine; D014439:Tyramine / Q000378:metabolism / Q000494:pharmacology
D000662:Amphetamines; D010627:Phenethylamines; D012642:Selegiline; D008995:Monoamine Oxidase; D014439:Tyramine